BSX catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
December 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Dec 30, 2026Sponsor estimate | NCT05501262Comparative Effectiveness of Cryoablation Versus Steroid and Lidocaine Alone for Treatment of Morton's NeuromaOregon Health and Science University · Morton Neuroma | BSXCollaborator | No phase registered | Recruiting | Locked | Locked | Locked |
| Dec 30, 2026Sponsor estimate | NCT05766943Reduction of Myopotential Interference With Smart Pass in S-ICD PatientsMedical University of South Carolina · Subcutaneous ICD | BSXCollaborator | No phase registered | Recruiting | Locked | Locked | Locked |
| Dec 31, 2026Sponsor estimate | NCT04694248Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein StentingFirst Affiliated Hospital of Zhejiang University · Deep Vein Thrombosis | BSXCollaborator | No phase registered | Recruiting | Locked | Locked | Locked |
- Primary completion Dec 30, 2026Sponsor estimateNo phase registeredNCT05501262Comparative Effectiveness of Cryoablation Versus Steroid and Lidocaine Alone for Treatment of Morton's NeuromaOregon Health and Science University · Morton NeuromaRecruitingBSXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimateNo phase registeredNCT05766943Reduction of Myopotential Interference With Smart Pass in S-ICD PatientsMedical University of South Carolina · Subcutaneous ICDRecruitingBSXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT04694248Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein StentingFirst Affiliated Hospital of Zhejiang University · Deep Vein ThrombosisRecruitingBSXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 1, 2027Sponsor estimate | NCT06523166Direct Comparison of Cardiac CT With TEE to Evaluate Watchman FLX LAA Occluder Device CharacteristicsUniversity Hospitals Cleveland Medical Center · Device Related Thrombosis | BSXCollaborator | No phase registered | Recruiting | Locked | Locked | Locked |
| Jan 31, 2027Sponsor estimate | NCT04004312Single Fractions SBRT for Prostate CancerFabio Cury · Prostate Cancer | BSXCollaborator | No phase registered | Recruiting | Locked | Locked | Locked |
| Jan 31, 2027Sponsor estimate | NCT05303467A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBMBoston Scientific Corporation · Glioblastoma Multiforme | BSXLead | Phase 1 | Recruiting | Locked | Locked | Locked |
- Primary completion Jan 1, 2027Sponsor estimateNo phase registeredNCT06523166Direct Comparison of Cardiac CT With TEE to Evaluate Watchman FLX LAA Occluder Device CharacteristicsUniversity Hospitals Cleveland Medical Center · Device Related ThrombosisRecruitingBSXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2027Sponsor estimateNo phase registeredNCT04004312Single Fractions SBRT for Prostate CancerFabio Cury · Prostate CancerRecruitingBSXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2027Sponsor estimatePhase 1NCT05303467A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBMBoston Scientific Corporation · Glioblastoma MultiformeRecruitingBSXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 15, 2027Sponsor estimate | NCT06510556Feasibility Study of the FARAFLEX Mapping and PFA SystemBoston Scientific Corporation · Atrial Fibrillation | BSXLead | No phase registered | Recruiting | Locked | Locked | Locked |
- Primary completion Feb 15, 2027Sponsor estimateNo phase registeredNCT06510556Feasibility Study of the FARAFLEX Mapping and PFA SystemBoston Scientific Corporation · Atrial FibrillationRecruitingBSXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 7 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.